Current clinical outcomes demand new treatment options for SCCHN

Annals of Oncology

Volumn 16, Issue SUPPL. 6, 2005, Pages

  Lefebvre, J L ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

Chemoradiotherapy; Chemotherapy; Head and neck cancer; Locally advanced; Radiotherapy; Recurrent metastatic

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; ISOTRETINOIN; METHOTREXATE; MITOMYCIN C; PLATINUM DERIVATIVE; RETINOL; TAMOXIFEN; TAXANE DERIVATIVE;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG FATALITY; DRUG POTENTIATION; DRUG TOLERABILITY; DYSPHAGIA; HEAD AND NECK CARCINOMA; HEAD AND NECK SURGERY; HUMAN; META ANALYSIS; METASTASIS; MUCOSA INFLAMMATION; OUTCOMES RESEARCH; PLASTIC SURGERY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SALVAGE THERAPY; SECOND CANCER; SQUAMOUS CELL CARCINOMA; STANDARDIZATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC SURGICAL PROCEDURES; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 27144517452     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi452     Document Type: Article

References (37)

1. GLOBOCAN 2002. http://www-dep.iarc.fr
2. Kowalski LP, Carvalho AL. Natural history of untreated head and neck cancer. Eur J Cancer 2000; 36: 1032-1037.
3. Tepperman BS, Fitzpatrick PJ. Second respiratory and upper digestive tract cancers after oral cancer. Lancet 1981; 2: 547-549.
4. Overgaard J, Hansen HS, Specht L et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomized controlled trial. Lancet 2003; 362: 933-940.
5. Awwad HK, Lotayef M, Shouman T et al. Accelerated hyperfractionation (AHF) compared to conventional fractionation (CF) in the post-operative radiotherapy of locally advanced head and neck cancer: Influence of proliferation. Br J Cancer 2002; 86: 517-523.
6. Browman GP, Hodson DI, Mackenzie RJ et al. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with sub-group analysis. Head Neck 2001; 23: 579-589.
7. Bourhis J, Armand C, Pignon JP. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head&Neck Cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (14S): Abstr 5505.
8. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-955.
9. Rhee JC, Khuri FR, Shin DM. Advances in chemoprevention of head and neck cancer. Oncologist 2004; 9: 302-311.
10. Toma S, Bonelli L, Sartoris A et al. 13-cis retinoic acid in head and neck cancer chemoprevention: Results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group. Oncol Rep 2004; 11: 1297-1305.
11. van Zandwijk N, Dalesio O, Pastorino U et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000; 92: 977-986.
12. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
13. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952.
14. Licitra L, Vermorken JB. Is there still a role for neoadjuvant chemotherapy in head and neck cancer? Ann Oncol 2004; 15: 7-11.
15. Licitra L, Grandi C, Guzzo M et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: A randomized controlled trial. J Clin Oncol 2003; 21: 327-333.
16. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324: 1685-1690.
17. Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890-899.
18. Lefebvre JL, Chevalier D, Luboinski B et al. Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (14S): Abstr 5531.
19. Gillespie MB, Brodsky MB, Day TA et al. Swallowing-related quality of life after head and neck cancer treatment. Laryngoscope 2004; 114: 1362-1367.
20. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098.
21. Bensadoun RJ, Dassonville O, Ramaioli A et al. Phase III multicenter randomized study of concurrent twice-a-day radiotherapy with and without cisplatin (BiCRF) in unresectable pharyngeal carcinoma. Results at 18 months (FNCLCC-GORTEC). J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (14S): Abstr 5504 and virtual presentation http://www.asco.org.
22. Maguire PD, Meyerson MB, Neal CR et al. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community. Int J Radiat Oncol Biol Phys 2004; 58: 698-704.
23. Budach VG, Stuschke M, Budach W et al. Accelerated hyperfractionated chemoradiation (C-HART) plus 5-FU/MMC is superior to HART for inoperable locally advanced head and neck cancer. Final results of the German ARO 95-06 multicentre trial. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (14S): Abstract 5503 and virtual presentation http://www.asco.org.
24. Nguyen NP, Moltz CC, Frank C et al. Dysphagia following chemoradiation for locally advanced head and neck cancer. Ann Oncol 2004; 15: 383-388.
25. Pivot X. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of squamous cell carcinoma of the head and neck. Ann Oncol 2003; 14: 1014-1015.
26. Vermorken JB, Remenar E, Van Herpen C et al. Standard cisplatin/ infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): A phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (14S): Abstract 5508.
27. Morton RP, Rugman F, Dorman EB et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: A randomized factorial phase III controlled trial. Cancer Chemother Pharmacol 1985; 15: 283-289.
28. Jacobs C, Lyman G, Velez-Garcia E et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257-263.
29. Clavel M, Vermorken JB, Cognetti F et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5: 521-526.
30. Wittes RE, Cvitkovic E, Shah J et al. CIS-Dichlorodiammineplatinum(II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 1977; 61: 359-366.
31. Spencer SA, Harris J, Wheeler RH et al. RTOG 96-10: Reirradiation with concurTent hydroxymea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 2001; 51: 1299-1304.
32. Schaefer U, Micke O, Schueller P, Willich N. Recurrent head and neck cancer: Retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study. Radiology 2000; 216: 371-376.
33. Leon X, Hitt R, Constenla M et al. A retrospective analysis of the outcome of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) who are progressing while on a platinum-based palliative chemotherapy. Proc Am Soc Clin Oncol 2003; 22: Abstract 2202.
34. Bonner JA, Giralt J, Harari P et al. Cetuximab prolongs survival in patients with locally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (14S): Abstr 5507.
35. Burtness BA, Li Y, Flood W et al. Phase III randomized trial of cisplatin + placebo versus cisplatin + C225, a monoclonal antibody directed to the epidermal growth factor-receptor: An Eastern Cooperative Oncology Group trial. Clin Cancer Res 2003; 9: Abstr A77.
36. Baselga J, Trigo JM, Bourhis J et al. A phase II multicenter study of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2005; in press.
37. Kies MS, Arquette MA, Nabell L et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2002; 21: Abstr 925. Virtual Meeting at http://www.asco.org.